Mohammad Alashqar Shares Novel Antithrombin-Targeting Therapy for Hemophilia A and B
Mohammad Alashqar, Postdoctoral Pharmacotherapy Research Fellow at The Ohio State University College of Pharmacy, shared on LinkedIn:
“Grateful to share that my review paper, ‘Fitusiran: A Novel Antithrombin-Targeting Therapy for Hemophilia A and B, With or Without Inhibitors,’ has been published online today (12/26)
Sincere thanks to everyone who supported me throughout this journey—especially Dr. Milap Nahata for his mentorship, guidance, and invaluable feedback. This work would not have been possible without such support.
Looking forward to continuing contributions to hemophilia and thrombosis research.
Title: Fitusiran: A Novel Antithrombin-Targeting Therapy for Hemophilia A and B, With or Without Inhibitors
Authors: Mohammad Alashqar, Milap Nahata
Read the article.”
Deepen your hematology knowledge with Hemostasis Today.
-
Oct 13, 2026, 21:05Francisco Chacón-Lozsán: Heparin-Induced Thrombocytopenia – When an Anticoagulant Triggers Thrombosis
-
Oct 13, 2026, 21:04Aref Zribi: Isolated Tumor Thrombus and the Role of Prophylactic Anticoagulation
-
Oct 13, 2026, 21:01Alex Larson: Why Normal Bloodwork Does Not Always Tell the Whole Story
-
Oct 13, 2026, 20:58Juan Jauregui-Lozano: How Replication Stress Impairs Red Blood Cell Maturation
-
Oct 13, 2026, 20:55Caitlin Raymond: Understanding Platelet Refractoriness Before Ordering More Platelets
-
Oct 13, 2026, 20:54Sanja Seratlic: How Cow Feeding Systems Influence the Anti-Platelet Properties of Cheddar Cheese
-
Oct 13, 2026, 20:50Ruchika Goel: Cord Blood Red Blood Cells as a Physiologically Aligned Transfusion Strategy
-
Oct 13, 2026, 20:47Sophia Delicou: Strengthening Transfusion Safety Through Advanced Screening and Haemovigilance
-
Oct 13, 2026, 20:45Lydia Pecker: Alloimmunization and Transfusion Indications in Sickle Cell Disease Pregnancy